Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 22,2022
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
​Recently, Shanghai Medicilon Inc. (Medicilon) signed a strategic collaboration agreement with Infinite Intelligence Pharma (IIP).
More
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
Nov 22,2022
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
On November 10, 2022, the Listed Companies Association of Shanghai held the 4th member meeting of the association and the 1st meeting of council of the association through the online platform of East Money information. The meeting was presided over by Yuan Yi, Secretary of the Association, and supervised by the Shanghai Oriental Notary Public Office.
More
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
Nov 18,2022
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Medicilon offer a full range of chemistry Research services covering all phases of your project requirements, and clients can work with us under either the FFS (project-based payment) or FTE (full-time equivalent service) models.
More
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 08,2022
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
On August 29, 2022, Beijing Peptide Biomedical Technology Co., Ltd. (Bejing Peptide) ZT002 injection was approved by the Australian Human Research Ethics Committee for Phase I clinical trials.
More
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
Nov 08,2022
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Recently, Shanghai Medicilon Inc. (Medicilon) appointed Dr. Renzong Xie as the Vice President of Toxicology Research Department.
More
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Oct 28,2022
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.
More
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
Oct 21,2022
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Shanghai Medicilon Inc. was awarded the honorary title of "Top 30 Listed Companies on the Science and Technology Innovation Board".
More
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Oct 19,2022
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of CMC.
More
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Sep 29,2022
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Recently, Ringene Biopharma, an innovative drug R&D company focusing on the development of drugs targeting RTK-RAS-MAPK signaling pathway, independently developed a new class of anti-tumor drugs, the irreversible pan-FGFR inhibitor RG002, which was approved clinical. The indications are advanced malignant tumors.
More
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Sep 29,2022
Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration
On September 20, 2022, OBiO Technology (OBiO) and Shanghai Medicilon Inc. (Medicilon) held a signing ceremony of strategic collaboration in the field of gene and cell therapy services.
More
Collaboration to empower gene therapy, OBiO Technology and Medicilon reach a strategic collaboration
Sep 26,2022
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
On September 21, 2022, Medicilon (Baoshan) Inc's, a subsidiary of Shanghai Medicilon Inc, groundbreaking ceremony was held in North Shanghai Parmaceutical Industrial Park. This is another grand event following the opening of Medicilon (Hangzhou) on September 7.
More
The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) was successfully held
Sep 14,2022
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!
On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou.
More
Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!